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Improving walking ability and ankle
brachial pressure indices in symptomatic
peripheral vascular disease with
intermittent pneumatic foot compression:
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John H. N. Wolfe, MS, FRCS, and Gerard Stansby, MChir, FRCS, London,
United Kingdom
Purpose: Intermittent pneumatic foot compression (IPCfoot) augments arterial leg inflow.
It has been suggested that prolonged use of impulse leg compression at home might
ameliorate claudication caused by peripheral vascular disease by improving collateral cir-
culation. The purpose of this study was to determine the effect of IPCfoot treatment on
claudication distance and arterial hemodynamics in patients with intermittent claudica-
tion caused by peripheral vascular disease.
Methods: Thirty-seven patients with stable intermittent claudication were admitted to
this prospective controlled study. Of these, 25 patients received IPCfoot (>4 hr/d) for
4.5 months (group 1), and the other 12 patients acted as control patients (group 2).
Both groups were advised to exercise unsupervised for a minimum of 1 hour daily and
received aspirin (75 mg/d). Groups were matched for age, sex, risk factors, claudication
distances, and ankle pressures at baseline. In each patient, initial claudication distance
(ICD), absolute claudication distance (ACD), resting ankle brachial index (r-ABI), ankle
brachial pressure index after exercise (p-eABI), and popliteal artery volume flow were
measured at day 0, 2 weeks, and 1, 2, 3, and 4.5 months. On completion of the treat-
ment period (4.5 months), both groups continued with aspirin (75 mg/d) and unsu-
pervised exercise and were re-examined after 12 months. Data analysis is based on non-
parametric statistics, the Wilcoxon signed ranks test, and the Mann-Whitney test for
intragroup and intergroup comparisons, respectively. Results are expressed as median
and interquartile ranges.
Results: Over the 4.5 months of active treatment, (1) median ICD in group 1 increased
by 146% (P < .001), from 78 m (interquartile range, 65-102 m) at baseline to 191.5 m
(interquartile range, 127-254 m); ICD did not significantly increase in group 2; (2)
median ACD in group 1 improved by 106% (P < .001), from 124 m (interquartile range,
100-160 m) to 255 m (interquartile range, 149-398 m); no significant changes were
documented in group 2; (3) median r-ABI in group 1 rose by 18% (P < .001), from 0.57
(interquartile range, 0.48-0.62) to 0.67 (interquartile range, 0.64-0.70); no improve-
ment was noted in group 2; (4) median p-eABI in group 1 rose by 110% (P < .001),
from 0.21 (interquartile range, 0.07-0.27) to 0.44 (interquartile range, 0.36-0.52); no
changes were noted in group 2; and (5) median popliteal artery volume flow in group 1
improved by 36% (P < .001), from 100 mL/min (interquartile range, 59-163 mL/min)
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Lower extremity claudication caused by athero-
sclerotic occlusive disease affects an estimated 10%
of the population over age 70 years1-3 and 2% to 3%
of individuals aged 37 to 69 years,3-5 with a signifi-
cant impact on quality of life.6-8 The aging popula-
tion in Western societies indicates that its prevalence
will increase significantly over the next decades.9
Recent objective studies on the natural history of
claudication have demonstrated deterioration of
symptoms in 22% to 60% of patients.10-13 As the use
of the most effective pharmacologic agents results
only in a modest improvement in claudication,14-16
participation in a structured program of regular
exercise,17-19 control of associated medical diseases
or risk factors, surgical revascularization, and percu-
taneous transluminal angioplasty are currently con-
sidered the most beneficial management options.
Unfortunately, perioperative death, long-term graft
failures,20-23 and contraindications to24 or limita-
tions25-27 of infrainguinal percutaneous transluminal
angioplasty militate against active intervention for
claudication.
Recently, mechanical methods have emerged as
an effective means of augmenting arterial volume
flow in the lower limbs of patients with peripheral
vascular disease (PVD). Resting popliteal artery vol-
ume flow in seated claudicants was found to increase
3.2 ± 1.6 times (±SD) with the application of inter-
mittent pneumatic calf compression28 and by 51% to
84% with intermittent pneumatic foot compres-
sion.29-31 Arterial flow increased substantially in legs
with rest pain when intermittent foot and calf com-
pression were exerted simultaneously.32 Using iso-
topes, Gaskell and Parrott33 demonstrated enhance-
ment of arterial inflow to the calf on application of a
mechanical venous foot pump.
Although the acute effect of intermittent pneu-
matic limb compression on volume flow has been
studied, its therapeutic potential on a long-term
basis in patients with intermittent claudication
(Fontaine II) has not been examined. The aim of
this prospective study was to evaluate the effect of
intermittent pneumatic foot compression, used
daily, for a few months on the claudication distance
and lower limb arterial hemodynamics in patients
with stable intermittent claudication.
MATERIALS AND METHODS
Study design. Patients meeting the inclusion
and exclusion criteria (Table I) and after stratifica-
tion for smoking and diabetes were allocated to
groups 1 and 2, with a ratio of 2:1, respectively. In
every three new eligible entries into each of the
stratification subgroups, two subjects were entered
into group 1 and one subject was entered into group
2; the allocation was made by an independent indi-
vidual. Patients in group 1 received intermittent
pneumatic foot compression (IPCfoot) for 4 hours
each day plus 75 mg aspirin daily for 4.5 months.
Patients in group 2 received 75 mg aspirin daily for
4.5 months. Both groups were advised to exercise
for a minimum of 1 hour per day. This is part of the
routine advice given to patients with claudication in
our outpatient clinics.
After 4.5 months, group 1 patients ceased using
IPCfoot. Groups 1 and 2 continued unsupervised
exercise and taking aspirin (75 mg/d) for another
12 months.
Inclusion and exclusion criteria. Patients includ-
ed into the study had superficial femoral artery occlu-
sion, aortoiliac vessels free of hemodynamically signif-
icant disease (as confirmed by a recent [30 days]
angiogram or duplex ultrasonography), a patent
popliteal artery with minimal atherosclerotic lesions,
stable intermittent claudication (Fontaine II; with
absolute claudication distance more than 40 m, but
no better than 300 m, determined by treadmill [3.8
km/h, 10% gradient]), and only unilateral intermit-
tent claudication at baseline. The exclusion criteria
used in the study are shown in Table I.
Patients. The long-term effect of IPCfoot was
studied in 25 patients with stable intermittent clau-
to 136 mL/min (interquartile range, 99.5-173.4 mL/min); no significant changes were
found in group 2. At 4.5 months, ICD, ACD, r-ABI, and p-eABI in group 1 were all
significantly better than those in group 2 (P < .01). Twelve months’ posttreatment,
walking ability and ABIs in group 1 were not statistically different from those at 4.5
months and remained significantly better than those of control subjects.
Conclusion: Intermittent pneumatic foot compression used at home for 4.5 months
increases claudication distance by over 100%. Associated increases in r-ABI by 18%, p-
eABI by 110%, and arterial calf inflow by 36% suggest an improved collateral circula-
tion. Maximum benefit seems to be offered over the initial 3 months. Treatment bene-
fits are maintained 1 year after treatment. A multicenter study is indicated to quantify
actual benefits and to demonstrate cost effectiveness. (J Vasc Surg 2000;31:650-61.)
JOURNAL OF VASCULAR SURGERY
652 Delis et al April 2000
dication (Fontaine II; group 1). The control group
(group 2) consisted of 12 stable claudicants. Patient
demographics are shown in Table II. The two study
groups were matched for age, sex, claudication dis-
tance, hemodynamics, and risk factors (Table II). A
scattergram of the baseline claudication distances
and hemodynamics is shown in Fig 1.
The duration of symptoms (mean ± SD) in
groups 1 and 2 was 2.6 ± 1.2 and 2.3 ± 1.1 years,
respectively (P > .1), with the onset of claudication
and recovery time remaining clinically unchanged
for at least 12 months (more than 18 months, except
three patients with unchanged claudication for just
over 12 months) before their inclusion in this trial.
IPCfoot. IPCfoot was delivered with the use of
the A-V Impulse System (Novamedix, Andover,
Hampshire, UK). This is a mechanical pneumatic
pump (consisting of a pneumatic impulse generator
and a plastic inflatable pad) applied firmly to the foot
by means of a specially developed slipper. The gen-
erator is comprised of an electrically driven air com-
pressor and an air reservoir that vents intermittently
into the pneumatic foot pad. Investigation through-
out the study was conducted with the pump operat-
ing at the following settings: maximum inflation
compression, 180 mm Hg; minimum deflation pres-
sure, 0 mm Hg; inflation time, 3 seconds; deflation
time, 17 seconds; and rise time <0.2 seconds.
The use of these settings was decided on the
basis of the hemodynamically significant direct effect
they generate in the popliteal artery.31 The applica-
tion time of IPCfoot per day, in the absence of previ-
ously published data in the literature, represents a
compromise between a substantially long-acting
pneumatic stimulus, the ability to deliver well-sus-
tained arterial calf inflow enhancement, and the
patients’ tolerance of the treatment, ensuring good
compliance. Patients were allowed to split this time
in two or three periods, to suit their daily schedules.
Compliance was evaluated by means of a timer of
pump action, located at the back of the equipment.
Patients were unaware of its measuring function
throughout the active treatment period.
Examination and scanning protocol. Patients
were examined on six consecutive occasions: at base-
line, after 2 weeks, at the end of months 1, 2, 3, and
4.5 (treatment period). Patients of both study
groups were finally reexamined 12 months after the
completion of the treatment period to evaluate the
long-term effect of the lower limb impulse treat-
ment. Each session entailed examination of the fol-
lowing measurements: (1) resting ankle brachial
index (r-ABI); (2) ABI after exercise (p-eABI), as
determined after a 1-minute treadmill test at 4.0
km/h and 10% inclination; (3) initial (pain-free)
claudication distance (ICD) and absolute claudica-
tion distances (ACDs), evaluated by treadmill exer-
cise at a speed of 3.8 km/min and 10% inclination,
and (4) resting popliteal artery volume flow in the
recumbent position, as estimated by color flow
duplex imaging.
The investigation started with the measurement
of popliteal artery volume flow. A resting period of
20 minutes was allowed in the horizontal position
before the examination. Popliteal artery volume flow
measurements were performed with our HP 2500
color flow duplex scanner (Sonos; Hewlett Packard,
Palo Alto, Calif) through a 7.5/5.5 MHz linear
array probe. The volume flow was calculated by mul-
tiplying the time averaged velocity over a minimum
of five cardiac cycles by the cross-sectional area of
the popliteal artery. A minimum of five flow estima-
tions was obtained on each investigation session per
patient per leg, and the average was used. The tech-
nique and its reproducibility have been previously
described.31 The patients were examined in the
recovery position (lying horizontal on their side)
with the investigated leg uppermost and nearer the
examiner.
After popliteal artery volume flow measurement,
patients underwent r-ABI, p-eABI (first treadmill),
ICD, and ACD (second treadmill) evaluation. There
was a minimum rest period of 30 minutes between
the two treadmill tests (the 1-minute walk being the
first). The site of optimal Doppler signal in the foot,
Table I. Exclusion criteria
Chronic respiratory insufficiency
Coronary artery disease and angina
Chronic cardiac insufficiency
Shortness of breath before or with the onset of claudication
Symptomatic chronic venous disease (CEAP classes 2-6)34
Degenerative or inflammatory hip, knee, ankle, or foot joint
lesions interfering with walking
Sciatica or spinal-intervertebral disc lesions with lower limb
motor sensory defects
Leg trauma, inflammation, ulceration, or edema
Recent (12 months) abdominal, cardiothoracic, or orthopedic
(lower limb) surgery
Uncontrolled hypertension
Vasoactive medication
Long-term (>5 years) insulin-dependent diabetes mellitus 
Aneurysmatic disease
Morbid obesity
Vasospastic syndromes
PVD in the nonsymptomatic (contralateral) leg consistent
with an ABI decrease after exercise >20% and a p-eABI
≤0.65 (4.0 km/min, 10% for 1 minute).
CEAP, Clinical, Etiologic, Anatomic, Pathophysiologic.
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along the course of posterior tibial or dorsalis pedis
arteries, was marked at rest to assist accurate assess-
ment of p-eABIs. P-eABIs were obtained at 1
minute after exercise with the aid of the same sphyg-
momanometers and programmed time watch.
ABI was measured by dividing the higher ankle
pressure (obtained from the dorsalis pedis or the pos-
terior tibial arteries) with the higher of the two
brachial artery pressures, as described by Yao.35,36 All
pressure estimations were obtained in the horizontal
position, with a continuous-wave Doppler detector
(Dyna D 800; AHS, Paris, France). The technologist
performing the test was completely blinded as to
which treatment the patients received. A diagram of
the examination protocol is given in Table III.
All investigations were performed in tempera-
Table II. Demographics, walking ability, hemodynamics, and risk factors in the study groups.
Group 1 Group 2 Significance 
(n = 25)* (n = 12)† (group 1 vs 2)
Male/female 17/8 7/5 NS‡
Age (y; range) 68 (58-81) 65 (60-78) NS§
ICD (m; interquartile range) 78 (65-102) 69 (50-92) NS§
ACD (m; interquartile range) 124 (100-160) 134 (89-202) NS§
r-ABI (interquartile range) 0.57 (0.48-0.62) 0.56 (0.52-0.6) NS§
p-eABI (interquartile range) 0.21 (0.07-0.26) 0.24 (0.17-0.3) NS§
Popliteal artery volume flow (mL/min; interquartile range) 100 (59-163) 110 (70-155) NS§
Smoking (n) 1/25 1/12 NS‡
Diabetes mellitus (n) 3/25 1/12 NS‡
*IPCfoot + aspirin.
†Aspirin.
‡Chi-square test (P > .05).
§Mann-Whitney test (P > .05).
Fig 1. Performance distribution diagram of studied claudicants (group 1, IPCfoot; group 2,
control). (vFl for Volume flow.)
(meters) (meters)
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ture-controlled conditions (22°C ± 1°C). Patients
attended morning appointments allocated always at
the same time.
Analysis of the results was performed with non-
parametric (two-sided) statistics with 95% confidence
intervals (95% CI) of the estimated median of the dif-
ference in measurements (Minitab, Inc, State
College, Pa). When comparisons were made within
the same study group, the Wilcoxon signed ranks test
for paired data was applied. Comparisons between
the two groups was conducted with the Mann-
Whitney ranking test for unpaired data. Whenever
the same test was applied more than once within the
same data setting, Bonferoni corrections were
applied. Univariate linear regression analysis was per-
formed to establish associations. Data are presented
as median and interquartile range. A probability
value equal to or less than .02 was the threshold of
statistical significance throughout the study.
RESULTS
Over the 4.5 months of active treatment, the
walking ability, systolic ankle pressures, and popliteal
artery volume flow increased significantly among
patients who received IPCfoot (group 1). No signifi-
cant improvements in either walking ability or hemo-
dynamics were documented in the control subjects
(group 2) in the same period. Although both groups
were matched at baseline, group 1 had significantly
better walking capacity and ankle pressures than
group 2 at 4.5 months and 1 year after treatment.
Improvement in group 1 was universal but was not
related to the severity of baseline claudication.
Initial claudication distance. The median ICD
in group 1 increased from 78 to 183 m after 3
months of IPCfoot therapy and was 191.5 m on com-
pletion of 4.5 months of treatment (146% increase;
P < .001; Fig 2). The increments of ICD gained
over consecutive investigation sessions were all sta-
tistically significant until the end of month 3 (P <
.001). The rate of improvement in the ICD over the
last 6 weeks of treatment (3-4.5 months), however,
was less and did not reach statistical significance.
Improvement was universal in subjects of group 1,
with a percentage change in ICD at 4.5 months
ranging from 38% to 918% (median change, 110%).
There were no significant changes in the ICD seen
through the study period in group 2. When the two
groups were compared, group 1 was found to per-
form better after month 1 of the study (P = .0004;
95% CI: 30, 100 m). Twelve months after treat-
ment, the ICD in group 1 (200 m [interquartile
range, 140-275 m]) was not statistically different
from that at the end of the treatment period (P =
.94; 95% CI: –53, 66 m) and continued to be sig-
nificantly better than group 2 (P < .0001; 95% CI:
70, 200 m).
Absolute claudication distance. The ACD in
group 1 increased from 124 m (interquartile range,
100-160 m) on day 0 to 245 m (interquartile range,
185.3-403.3 m) by the end of month 3 and was
slightly higher at the end of the treatment (4.5
months; 255 m [interquartile range, 149-398.3 m]),
representing a median overall progress of 106% (P <
.001; Fig 3). As with the ICD, all the improvements
recorded over the consecutive study sessions within
group 1 were statistically significant through to the
end of month 3. The rate of improvement in the last
6 weeks of the active treatment period showed a
marked attenuation compared with the first 3
months, and changes encountered in this 6-week
period were not statistically significant (P = .63).
Improvement was universal in subjects of group 1,
with a percentage change in ACD at 4.5 months
that ranged from 18% to 797% (median, 110%). The
ACD in group 2 did not improve throughout the
Table III. Examination protocol of patients in study groups 1 (IPCfoot) and 2 (control patients)
Active treatment Follow-up 
Group period (mo) (mo)
Preliminary phase allocation Baseline 0.5 1 2 3 4.5 16.5
Inclusion and Group 1 (IPCfoot + aspirin) Flow Flow Flow Flow Flow Flow —
exclusion criteria ABIs ABIs ABIs ABIs ABIs ABIs ABIs
ICD ICD ICD ICD ICD ICD ICD
Examination ACD ACD ACD ACD ACD ACD ACD
Group 2 (aspirin) Flow Flow Flow Flow Flow Flow —
ABIs ABIs ABIs ABIs ABIs ABIs ABIs
Duplex/angiogram ICD ICD ICD ICD ICD ICD ICD
treadmill ACD ACD ACD ACD ACD ACD ACD
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study period. When the two groups were compared,
group 1 performed better as early as month 2 (P <
.02; 95% CI: 9, 196 m). Twelve months after treat-
ment, the ACD in group 1 (230 m [interquartile
range, 150-453 m]) was not statistically different
from that at month 4.5 (P = 0.95; 95% CI: –103, 91
m) and continued to be significantly better than that
of group 2 (P = .004; 95% CI: 40, 320 m).
Resting-ankle brachial index. The r-ABI in
group 1 improved from 0.57 (interquartile range,
0.48-0.62) at baseline to 0.68 (interquartile range,
0.65-0.70) by the end of month 3 and was 0.67
(interquartile range, 0.64-0.70) at month 4.5 (P <
.001). The r-ABI increments recorded over the con-
secutive investigation sessions were all statistically sig-
nificant until week 4 (Fig 4). In group 2, changes in
r-ABI were not significant. Group 1 had better r-ABI
as early as the end of month 2 (P = .017; 95% CI:
Fig 2. ICD in meters (median and interquartile range) in groups 1 (IPCfoot) and 2 (control
subjects) over the time points of the study. ICD in group 1 was better than in group 2 as early
as the end of month 1 (P = .0004; 95% CI: 30, 100 m).
Fig 3. ACD in meters (median and interquartile range) in groups 1 (IPCfoot) and 2 (control
subjects) over the time points of the study. ACD in group 1 was better than in group 2 as early
as month 2 (P < .02; 95% CI: 9, 196 m).
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0.015, 0.20). Twelve months after the end of treat-
ment, the r-ABI in group 1 (0.67 [interquartile range,
0.60-0.72]) was not statistically different from that at
month 4.5 and continued to be significantly better
than that of group 2 (P = .01; 95% CI: 0.02, 0.2).
P-eABI. The p-eABI in group 1 increased from
0.21 (interquartile range, 0.07-0.27) to 0.43
(interquartile range, 0.39-0.48) at the end of month
3 and was 0.44 (interquartile range, 0.36-0.52) at
month 4.5 (110% increase; P < .001). Increases
between the consecutive investigation sessions until
the end of month 3 were all statistically significant (P
< .01). The improvement was attenuated over the last
6 weeks (3-4.5 months; Fig 5). Changes in p-eABI for
group 2 were not significant. Group 1 had a signifi-
cantly higher p-eABI than group 2 as early as the end
of month 2 (P = .009; 95% CI: 0.034, 0.21). Twelve
months after the end of treatment, the p-eABI (0.29
Fig 4. r-ABI (median and interquartile range) in groups 1 (IPCfoot) and 2 (control subjects) over
the time points of the study. The r-ABI in group 1 was better than in group 2 as early as month
2 (P = .017; 95% CI: 0.015, 0.20).
Fig 5. p-eABI (median and interquartile range) in groups 1 (IPCfoot) and 2 (control subjects)
over the time points of the study. Group 1 had a better p-eABI than in group 2 as early as
month 2 (P = .009; 95% CI: 0.034, 0.21).
by 93% in normal individuals (P < .0001) and 84% in
patients with PVD (P < .03). These results are con-
firmed by a more recent study, conducted in our
department, that shows that flow increases by 110% in
normal individuals (P < .0001) and by 50% in patients
with claudication (P < .0001), while IPCfoot is being
applied.31 That study examined the direct effect of
IPCfoot on arterial flow and discovered major changes
in the end diastolic velocity and the pulsatility index,
which suggested that flow enhancement was probably
the result of a marked decrease in peripheral resistance
to flow.
Two possible etiologic mechanisms may explain
the arterial calf inflow enhancement on application
of IPCfoot: (1) an increase of the arteriovenous pres-
sure gradient as the result of the lower limb venous
emptying28-30,37 and (2) the production of endothe-
lial derived vasodilating factors (such as nitric oxide
and prostacyclin) as the result of increased shear
stress.42-45 Another potential causative factor that
merits consideration is the transient suspension of
the venoarteriolar reflex as the venous pressure
decreases after the delivery of pneumatic foot
impulse.46 The venoarteriolar reflex is a local sympa-
thetic (axon) reflex that, on elevation of the venous
pressure, causes precapillary sphincters to contract
and peripheral resistance to increase, with a conse-
quent decrease of arterial calf inflow.47-48
This study demonstrates that the long-term
application of IPCfoot is an effective treatment in
symptomatic PVD. Patients who complained of
intermittent claudication for more than 2 years and
whose symptoms had been stable for at least 1 year
before their inclusion in the present trial demon-
strated a marked improvement of their condition
within 4.5 months of treatment with IPCfoot. The
baseline median ICD for group 1 increased by 131%
by month 3 and reached 146% by month 4.5.
Improvement occurred unequivocally in all subjects,
and the smallest increase in this group was 38%.
Three subjects (12%) improved their walking to the
extent that they could continue exercising on the
treadmill beyond 1500 m with no claudication.
The beneficial effect of the limb compression treat-
ment on the onset and severity of claudication was
directly reflected in the ACD performance of group 1.
With IPCfoot, the median ACD improved by 95% in 3
months and reached 106% at 4.5 months. The rate of
improvement was highest over the initial 3 months of
treatment. Over the initial 4 weeks, the highest rate of
improvement in group 1 coincided with the maximal
rate of ankle pressure changes. The overall median p-
eABI increase over the 4.5 months was 110%. Again,
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[interquartile range, 0.26-0.40]) was not statistically
different from that at month 4.5 and continued to be
higher than that in group 2 (95% CI: 0.001, 0.2).
Popliteal artery volume flow. Popliteal artery
volume flow in the horizontal position increased in
group 1 from 100 mL/min (interquartile range, 59-
163 mL/min) on day 0 to 136 mL/min (interquar-
tile range, 99.5-173.4 mL/min) at month 4.5 (36%
increase; P < .001). The peak volume flow was detect-
ed over months 2 and 3 (Fig 6). Changes in popliteal
artery volume flow for group 2 were not significant.
Intergroup comparison of volume flow just missed
statistical significance (P = .07) at 3 months.
Correlations. None of the changes that occurred
in objective measurements (r-ABI, p-eABI, and vol-
ume flow) from baseline to month 4.5 correlated well
with the improvements in the ICD and ACD docu-
mented in the same period. The best correlation was
obtained between the percentage of change in the p-
eABI and that for the ACD (r = 34; P > .05), followed
by that between the change in p-eABI, expressed as
absolute value difference, and the percentage of
change in ACD (r = 0.32; P > .1). Also, nonsignificant
correlations were found between baseline ICD, ACD,
r-ABI, p-eABI, or volume flow and the overall per-
centage improvement in either the ICD or ACD at
month 4.5 (all r < 0.26; P > .1).
DISCUSSION
Since the discovery of the venous foot pump in
1867 by Le Dentu, there has been limited investiga-
tion of its hemodynamic significance. Gardner and
Fox37 used video-phlebography to demonstrate
that, as the foot bears weight, the tarsometatarsal
joints extend and the tarsal arch flattens, causing the
plantar veins to eject their content (about 30 mL) to
the more proximal veins of the leg. This under-
standing of the physiologic role of the foot pump
stimulated research on the therapeutic implications
derived from its artificial activation. The delivery of
IPCfoot, in a manner that simulates the hemodynam-
ic action of normal walking, has been shown to be
effective in preventing deep vein thrombosis.38-41
The role of IPCfoot in augmenting arterial calf
inflow was hitherto missed. By injecting xenon Xe 133
subcutaneously, Gaskell and Parrott33 demonstrated
that a mechanical venous foot pump, delivering four
pneumatic impulses per minute, at a compression
higher than the ambulatory venous pressure, could
enhance blood flow by 80% in sitting arteriopaths.
Morgan et al,29 with the use of duplex ultrasonogra-
phy, reported that during a 5-minute pneumatic pump
action period, mean popliteal volume flow increased
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as occurred with the ICD and ACD, the changes
become apparent over the first 3 months with little
improvement thereafter. Thus the data of this study
indicate that, in terms of both walking ability and
hemodynamics, the impulse treatment reaches a
plateau by the end of month 3.
The pressure changes (r-ABIs and p-eABIs) seen
in group 1 suggest that the improvement in the
walking capacity obtained with the IPCfoot treat-
ment may be due to the enhancement of the collat-
eral circulation. This is strongly supported by the
significant increase in arterial calf inflow (group 1),
seen as early as month 2 of treatment. Because all
subjects had superficial femoral artery occlusion, this
must represent a flow increase through the collater-
al circulation. The overall changes documented in r-
ABI among individuals receiving IPCfoot (median
difference, 0.1045; 95% CI: 0.09, 0.16) are hemo-
dynamically significant according to the revised cri-
teria for reporting significant changes in clinical sta-
tus of chronic limb ischemia presented by
Rutherford et al.49 Fifteen subjects (15/25 subjects;
66.6%) in group 1 had an r-ABI increase greater
than 0.10, of whom 14 subjects also had an
improvement by one or two categories (moderate
hemodynamic improvement), within 4.5 months of
IPCfoot treatment. None of the subjects in this
group with an ABI increase of less than 0.10 sus-
tained a shift to a lower category.
Four main theories have been proposed regarding
the stimuli for the development of collateral circula-
tion. These include (1) an increase in the pressure gra-
dient across the arterial blockage,50 (2) an increase in
the volume flow and flow velocity around the block-
age,51 (3) an attenuation of the vasoconstrictor tone
in collateral vessels,52 and (4) the accumulation of
metabolites in tissues distal to the occluded 
segment.53 IPCfoot has not been proved to directly
affect the reduction in the collateral vessel wall tone or
the concentration of metabolites in the tissues distal
to the arterial blockage. It has been shown that
IPCfoot can enhance the arteriovenous pressure gradi-
ent by decreasing lower limb venous pressure54 and
can significantly augment both arterial calf inflow and
mean velocity.29-31 On this basis the daily application
of IPCfoot for at least 3 consecutive months could be
considered as a potent stimulus for the development
of collateral circulation.
The absence of significant improvements in the
control individuals, despite the close medical sur-
veillance and support fueling their motivation, was
not an unexpected finding. Unsupervised exercise in
patients with intermittent claudication as the result
of PVD has been shown to represent a treatment
option that yields insignificant benefit.55 One may
conclude that the treatment most frequently offered
(unsupervised exercise plus aspirin) is not the best
option for those with a stable incapacitating claudi-
Fig 6. Popliteal artery volume flow (vFl) in milliliters per minute (median and interquartile
range) in groups 1 (IPCfoot) and 2 (control subjects) over the time points of the study. The vol-
ume flow for group 1 at 2, 3, and 4.5 months, although consistently higher, was not signifi-
cantly different than that for group 2 (P ≥ .07).
cation. Lack of benefit in the control group of
patients with claudication (with or without placebo
treatment) has been reported by several investigators
in PVD studies.19,56-59
The absence of significant improvement with
IPCfoot in the period of 3 to 4.5 months could be
explained by assuming that the pneumatic stimulus
it provided was insufficient to promote further
hemodynamic changes, thus restricting its ability to
improve the walking capacity of treated patients with
claudication beyond a certain level.
A built-in timer at the back of the equipment,
the function of which was unknown to patients,
enabled monitoring of the active treatment period
among those patients receiving IPCfoot. In addition,
the presence in the machine of an alarm system that
was activated when the cuffs were inflated unloaded
(producing a loud noise and an automatic switch-off
within a few minutes) ensured that the timer’s indi-
cations equaled the actual IPCfoot usage time.
Patients’ compliance in the use of IPCfoot (4 hours
per day) was almost total, with more than 86% of
patients completing the scheduled treatment period
at the initial stages of the study on a monthly basis.
Compliance improved further with treatment time.
This could be attributed to the patients noticing the
actual benefits of IPCfoot, during their daily exercise.
Follow-up of the patients who received IPCfoot
treatment 1 year after its completion showed that
the walking capacity was consistently maintained,
despite some decrease (nonsignificant) in the p-
eABI. This indicates that the benefits of this treat-
ment are not short-lived but may be maintained for
a substantial period of time. Maintenance of the
improvements may have been reinforced by the
longer distances walked, thus the more intense and
longer-lived hyperemic periods sustained in the
peripheral circulation in the year after treatment.
The significant increase in the p-eABI during the
period 0 to 3 months by 105%, when the r-ABI
improved by 19.3%, is reversed to some extent in the
year after IPCfoot treatment by a 34% decrease in the p-
eABI, in the absence of changes in the r-ABI. Although
the benefits in walking capacity gained during the latter
period were maintained after treatment, this may indi-
cate that the p-eABI is a more sensitive parameter of
early hemodynamic changes compared with the r-ABI.
In the presence of superficial artery occlusion, the r-
ABI reflects the pressure gradient as modulated
through the open collateral vessels at rest, whereas the
p-eABI reflects the pressure gradient as modulated
through the collateral vessels that become patent after
a significant hemodynamic stimulation such as strenu-
ous exercise, in addition to those open at rest.
The level of improvement in the walking capaci-
ty of patients who received IPCfoot was neither par-
alleled by changes in popliteal artery flow and the
ABIs nor correlated by the severity of baseline clau-
dication. The percentage increases in the baseline
ICD and ACD at month 4.5 showed poor associa-
tions with any of the objective measurements
obtained, with the best correlation documented
between p-eABI and ACD (r = 0.34) being nonsta-
tistically significant (P > .05). Poor associations were
also found between the baseline ICD and ACD in
group 1 and the improvements in walking at 4.5
months (r < 0.2; P > .1). These findings suggest that
the hemodynamic improvement could not be the
only mechanism involved in explanation of the
increases in the walking ability of claudicants. Other
mechanisms, such as improved lower limb muscle
conditioning and performance that occur with phys-
ical training of patients with claudication,57,60 may
also have contributed to the achieved results.
The results achieved by the IPCfoot treatment are
superior to those published on the best medical treat-
ment and are on a par with those presented for 
well-conducted supervised exercise programs. In a
meta-analysis of all published randomized, placebo-
controlled, double-blind clinical trials that evaluated
the true effect of pentoxifylline on the claudication
distance of patients with moderate intermittent 
claudication (a total of 11 studies), Hood et al16
demonstrated that the treated group performed bet-
ter than the placebo-control group, but the weighted
mean difference was only 29.4 m (95% CI: 13 m,
45.9 m) for the ICD and 48.4 m (95% CI: 18.3 m,
78.6 m) for the ACD. In another meta-analysis of all
published randomized studies on the effect of super-
vised exercise programs on the walking capacity of
patients with claudication, the average increase was
179% for the ICD and 122% for the ACD.18 Despite
their confirmed effectiveness, supervised exercise 
programs are expensive to organize and maintain,
needlessly time-consuming, and often unavailable.
The long-term noncompliance rate can be as high as
65%.61 Evidence is accumulating more recently that
exercise itself may promote adverse inflammatory
changes that may be implicated in the excessive 
cardiovascular morbidity and mortality rates of
patients with claudication compared with the general
population.62 It has been suggested that an ischemia-
reperfusion phenomenon occurs with claudication,
resulting in formation of free radicals, neutrophil acti-
vation, and systemic vascular endothelial damage.62-64
In view of the high incidence and prevalence of
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intermittent claudication as the result of PVD, its
significant impact on quality of life,6-8 the ineffec-
tiveness of medical therapies, and the expense, risk,
and long-term high failure rates of both infrain-
guinal percutaneous transluminal angioplasty and
surgical revascularization,65 there is a requirement
for a complication-free, inexpensive, and rapidly
effective treatment option, as offered by IPCfoot.
The therapeutic implications of IPCfoot, stemming
from the results of this study, are vast. IPCfoot
appears to be effective in improving the walking
ability and hemodynamics in patients with stable
intermittent claudication. The conduction of ran-
domized prospective multicenter studies will enable
further evaluation of the actual benefits of this treat-
ment and the determination of its cost-effectiveness.
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